The hepatitis C virus (HCV) was discovered in the late 1980s. Interferon (IFN)-α was
proposed as an antiviral treatment for chronic hepatitis C at about the same time. Successive …

Hepatitis C virus (HCV) drug development has resulted in treatment regimens composed of
interferon‐free, all‐oral combinations of direct‐acting antivirals. While the new regimens are …

Nowadays, due to the development of potent Direct-Acting Antiviral Agents (DAAs) that
specifically target NS3, NS5A and NS5B viral proteins, several new and highly efficacious …

Modern viral kinetic modeling and its application to therapeutics is a field that attracted the
attention of the medical, pharmaceutical, and modeling communities during the early days of …

The development and clinical implementation of direct-acting antivirals (DAAs) has
revolutionized the treatment of chronic hepatitis C. Infection with any hepatitis C virus (HCV) …

One of the most exciting developments in antiviral research has been the discovery of the
direct-acting antivirals (DAAs) that effectively cure chronic hepatitis C virus (HCV) infections …

Background & Aims Direct-acting antivirals that target nonstructural protein 5A (NS5A), such
as daclatasvir, have high potency against the hepatitis C virus (HCV). They are promising …

Hepatitis C Virus (HCV) infects over 150 million people worldwide. In most cases HCV
infection becomes chronic, causing liver disease ranging from fibrosis to cirrhosis and …

Acyl-CoA: glycerol-3-phosphate acyltransferase (GPAT) and acyl-CoA: 1-acyl-glycerol-3-
phosphate acyltransferase (AGPAT) are involved in the de novo synthesis of triacylglycerol …

Hepatitis C virus (HCV) affects approx. 3% of the world's population and accounts for ca 300
000 deaths per year. 80% of individuals with HCV develop chronic symptoms which, when …